CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Meso BioMatrix Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01823107
NCT01823107N/ACompleted
CompareCT.gov

Meso BioMatrix Acellular Peritoneum Matrix Breast Reconstruction Feasibility Trial

Kensey Nash Corporation·interventional·Posted Apr 4, 2013·Updated Sep 10, 2019

In Brief

A clinical study evaluating Meso BioMatrix Device for Breast Cancer. Completed, enrolled 25 participants across 6 sites.

Detailed Summary

The purpose of the study is to evaluate the safety and feasibility of the use of Meso BioMatrix Acellular Peritoneum Matrix for the reinforcement of weakened soft tissue during 2-stage, tissue expander assisted breast reconstruction.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 4, 2013
Enrollment StartOct 1, 2012
Primary CompletionJun 1, 2017
Study CompletionJun 29, 2017
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 13.2 years ago

Interventions

Meso BioMatrix Devicedevice